

Expert Connect

All relationships are considered compensated. Relationships are self-held unless otherwise noted.

I = Immediate Family Member, Inst = My Institution

Name	Employment	Leadership	Stock and Other Ownership Interests	Honoraria	Consulting or Advisory Role	Speakers' Bureau	Research Funding	Patents, Royalties, Other Intellectual Property	Expert Testimony	Travel, Accommodations, Expenses	Other Relationship
Brian M. Alexander					Abbvie, Bristol-Myers Squibb, Precision Health Economics, Schlesinger Associates						
Nancy N. Baxter											
Harold J. Burstein											
Warren A. Chow						Novartis	Novartis (Inst)				
Don S. Dizon			InfiniteMD		Fuji Pharma, Pfizer, UpToDate		Aeterna Zentaris (Inst), Bristol-Myers Squibb (Inst)				
Andrew S. Epstein											UpToDate
Patricia A. Ganz		Intrinsic LifeSciences (I)	Abbott Laboratories, GlaxoSmithKline, Intrinsic LifeSciences (I), Johnson & Johnson, Merck, Merganser Biotech (I), Novartis, Pfizer, Silarus Therapeutics (I), Teva, Xenon Pharma (I)	Biogen (I)	InformedDNA, Keryx (I), Lilly, Merganser Biotech (I), Silarus Therapeutics (I), Vifor Pharma (I)		Keryx (I)	Related to iron metabolism and the anemia of chronic disease (I), UpToDate royalties for section editor on survivorship		Intrinsic LifeSciences (I), Keryx (I)	
Timothy D. Gilligan										WellPoint	
David L. Graham	Medscape	Medscape				Biopeps					
Daniel F. Hayes			InBiomotion, Onclmmune	Lilly			AstraZeneca (Inst), Janssen Research & Development (Inst), Lilly (Inst) Merrimack Pharmaceuticals, Parexel Intl Corp (Inst), Pfizer (Inst), Puma Biotechnology (Inst)	Royalties from licensed technology; Diagnosis and Treatment of Breast Cancer, Applicant Proprietor: University of Michigan, Dr. Daniel F. Hayes is designated as inventor/co-inventor; Circulating Tumor Cell Capturing Techniques and Devices, Applicant Proprietor: University of Michigan, Dr. Daniel F. Hayes is designated as inventor/co-inventor; A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells.		Janssen Diagnostics	

John Heymach			Bio-Tree, Cardinal Spine		Abbvie ARIAD, AstraZeneca Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, Genentech, Medivation, Novartis, Oncomed, Synta		AstraZeneca (Inst)				
Clifford A. Hudis					Lilly, Merck, Novartis, Pfizer, Roche/ Genentech						Breast Cancer Research Foundation
Stephen Hunger			Amgen, Amgen (I), Express Scripts, Merck (I), Pfizer (I)	ERYTECH Pharma, Jazz Pharmaceuticals, Spectrum Pharmaceuticals	Novartis			I am a co-Inventor on a US patent, Identification of novel subgroups of high-risk pediatric precursor-B acute lymphoblastic leukemia, outcome correlations and diagnostic and therapeutic methods related to same. It has not be licensed and there is no income.			
Bruce E. Johnson			KEW Group	Chugai Pharma, Merck	Amgen, AstraZeneca, Boehringer Ingelheim, Chugai Pharma, Clovis Oncology, Genentech, KEW Group, Lilly, Merck, Novartis, Transgene		Novartis (Inst)	Dana-Farber Cancer Institute	Genentech		
Joshua A. Jones											American Society for Radiation Oncology
David Khayat			Agenus		Atlantic Sante, Celtic Biotech, Fleury Michon, Genomic Health, SCM Lamallen Toledano Bollet						
Smitha S. Krishnamurthi							Celgene, CytomX Therapeutics, Nektar, Regeneron, Taiho Pharmaceutical				
Gary H. Lyman					G1 Therapeutics, Halozyme		Amgen (Inst)				
Merry J. Markham					Astex Pharmaceuticals		Aduro Biotech (Inst), Astex Pharmaceuticals (Inst)				
Gregory A. Masters											
Erica L. Mayer							Myriad Genetics, Pfizer				

Olatoyosi Odenike					Abbvie, Celgene, CTI/Baxalta, Incyte, Spectrum Pharmaceuticals, Sunesis Pharmaceuticals		Abbvie (Inst), Astex Pharmaceuticals (Inst), Celgene (Inst), Eisai (Inst), Gilead Sciences (Inst), Incyte (Inst), Janssen Oncology (Inst), Lilly (Inst), MEI-Pharma (Inst), Millennium (Inst), NS Pharma (Inst), Oncotherapy Sciences (Inst), Pfizer (Inst), S*Bio (Inst), Sanofi (Inst), Spectrum Pharmaceuticals (Inst), Sunesis Pharmaceuticals (Inst), Topotarget (Inst)				American Board of Internal Medicine (ABIM)
Sumanta K. Pal				Astellas Pharma, Medivation, Novartis	Astellas Pharma, Aveo, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Ipsen, Myriad Pharmaceuticals, Novartis, Pfizer		Medivation				
Jyoti D. Patel					Abbvie, ARIAD						
Charles J. Ryan				Astellas Pharma, Janssen Oncology	Bayer, Millennium		BIND Biosciences, Karyopharm Therapeutics, Novartis				
Michael S. Sabel								Breast Cancer Ally and Melanoma Ally mobile technologies.			
Lidia Schapira											
Richard L. Schilsky							AstraZeneca (Inst), Bayer (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), Lilly (Inst), Merck (Inst), Pfizer (Inst)				
Lynn M. Schuchter					Incyte		Bristol-Myers Squibb (Inst), GlaxoSmithKline (Inst), Merck (Inst)				
Julie Vose					Bio Connections		Acerta Pharma (Inst), Allos Therapeutics (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Genentech (Inst), Incyte (Inst), Kite Pharma (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst), Seattle Genetics (Inst)				